Breaking News Instant updates and real-time market news.

ALNY

Alnylam

$70.30

1.73 (2.52%)

, MDCO

The Medicines Co.

$38.51

0.32 (0.84%)

16:34
10/05/16
10/05
16:34
10/05/16
16:34

Alnylam ends revusiran development after nerve damage risk

Alnylam Pharmaceuticals (ALNY) announced that, upon the recommendation of the ENDEAVOUR Phase 3 study data monitoring committee to suspend dosing, the company has decided to discontinue development of revusiran, an investigational RNA interference therapeutic that was being developed for the treatment of hereditary ATTR amyloidosis with cardiomyopathy. "This decision was made yesterday evening and has been communicated to investigators, study sites, and regulatory authorities. Following recent reports in the Phase 2 OLE study of new onset or worsening peripheral neuropathy, the ENDEAVOUR DMC assembled yesterday at the company's request to review these reports and ENDEAVOUR data on an unblinded basis. The DMC did not find conclusive evidence for a drug-related neuropathy signal in the ENDEAVOUR trial, but informed the company that the benefit-risk profile for revusiran no longer supported continued dosing. The company subsequently reviewed unblinded ENDEAVOUR data which revealed an imbalance of mortality in the revusiran arm as compared to placebo... We remain committed to serving the needs of the ATTR amyloidosis community," the company explained. The company noted it will "continue to evaluate ENDEAVOUR data to understand the potential cause of these findings." The decision to discontinue development of revusiran does not affect patisiran, which is currently in Phase 3 development for the treatment of hATTR amyloidosis with polyneuropathy, or any other Alnylam investigational RNAi therapeutic program in development. Based on a current assessment of the safety data across the company's other programs, which include the ALN-PCSsc program partnered with The Medicines Company (MDCO), there is no evidence of a drug-related neuropathy signal in over 800 treated subjects and patients with exposure of up to 34 months. The company reaffirms its "Alnylam 2020" guidance and remains committed to the advancement of these investigational RNAi therapeutics.

ALNY

Alnylam

$70.30

1.73 (2.52%)

MDCO

The Medicines Co.

$38.51

0.32 (0.84%)

  • 14

    Oct

  • 06

    Nov

ALNY Alnylam
$70.30

1.73 (2.52%)

09/28/16
JANY
09/28/16
INITIATION
Target $74
JANY
Neutral
Alnylam initiated with a Neutral at Janney Capital
Janney Capital analyst Roy Buchanan initiated Alnylam with a Neutral and a $74 fair value estimate. The analyst is not confident about the outcome for the pivotal study for patisiran in transthyretin familial amyloid neuropathy, expected in about 12 months, and give patisiran a 50% chance of success.
09/15/16
FBRC
09/15/16
INITIATION
Target $82
FBRC
Underperform
FBR calls Alexion overvalued, starts shares at Underperform
FBR Capital analyst Christopher James initiated coverage of Alexion Pharmaceuticals (ALXN) with an Underperform rating and $82 price target. The biotech focused on patients with ultra-rare disorders closed yesterday up $2.63 to $129.42. Alexion shares are overpriced as the company is facing a competitive near-term landscape, particularly from Alnylam's (ALNY) ALN-CC5, James tells investors in a research note. Further, near-term expansion into additional indications will be challenging given the recent failed study with eculizumab in refractory generalized myasthenia gravis, the analyst contends. He also sees possible pricing pressures from biosimilars, including an Amgen (AMGN) biosimilar product in development. James this morning also initiated Achillion Pharmaceuticals (ACHN) and Arena Pharmaceuticals (ARNA) with Outperform ratings.
09/09/16
LEER
09/09/16
NO CHANGE
LEER
Leerink updates therapeutics best ideas for 2016
In a note to investors this morning, Leerink has updated its best ideas for 2016 from the firm's five therapeutics analysts. The list includes Alexion (ALXN), Dermira (DERM), Intra-Cellular (ITCI), Sanofi (SNY), Allergan (AGN), Alnylam (ALNY), Innate Pharma (IPHYF), The Medicines Co. (MDCO), and Ophthotech (OPHT).
08/22/16
WEDB
08/22/16
NO CHANGE
WEDB
Intellia Therapeutics data positive, says Wedbush
Wedbush analyst David Nierengarten says that additional data on Intella's (NTLA) TTR program in mice was "meaningful" and indicates that the program compares favorably with competing products. The analyst says that competing programs, including those of Alnylam (ALNY) and Ionis (IONS) have shown "only a transient benefit." He reiterates a $38 price target and Outperform rating on Intella.
MDCO The Medicines Co.
$38.51

0.32 (0.84%)

08/02/16
EVER
08/02/16
NO CHANGE
EVER
Buy
Pfizer shelves oral PCSK9, a Medicines Co. competitor, says Evercore ISI
Evercore ISI analyst Umer Raffat said Pfizer (PFE) management does not thin the profile for oral PCSK9 will be competitive with the strong efficacy of antibodies and have moved other interesting products forward. Raffat said some Medicines Co. (MDCO) investors had worried that a potential oral PCSk9 from Pfizer could greatly reduce enthusiasm for an every-6-month PCSk9 from MDCO. The analyst said the next catalyst for The Medicines Co. is A1 Milano readout this month. Raffat rates The Medicines Co. a Buy with a $52 price target.
07/11/16
JEFF
07/11/16
NO CHANGE
Target $43
JEFF
Buy
Jefferies views The Medicines Co. ruling as positive surprise
Jefferies analyst Biren Amin views today's Court of Appeals ruling as a "positive surprise" for The Medicines Company. The ruling "breathes potential life" into the company's Angiomax patents, Amin tells investors in a research note. He expects Hospira to file an appeal within 90 days. The analyst has a Buy rating on The Medicines Co. with a $43 price target.
05/13/16
JEFF
05/13/16
NO CHANGE
Target $43
JEFF
Buy
The Medicines Co. could rally $4/share on positive data, says Jefferies
Jefferies analyst Biren Amin says The Medicines Co. has a "catalyst-rich" second half of 2016, including the Phase III trials of Carbavance in complicated urinary tract infections and carbapenem resistant enterobacteriaceae infections. The analyst expects both of the trials will be successful and show non-inferiority leading to potential FDA approval. Amin thinks shares could move $3 to $4 per share on positive data readout. He keeps a Buy rating on The Medicines Co. with a $43 price target.

TODAY'S FREE FLY STORIES

DB

Deutsche Bank

$15.74

-0.32 (-1.99%)

17:07
12/02/16
12/02
17:07
12/02/16
17:07
Periodicals
Deutsche Bank to pay $60M settlement over gold price-fixing case, Reuters says »

Deutsche Bank will pay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jan

ALB

Albemarle

$84.86

-0.79 (-0.92%)

17:07
12/02/16
12/02
17:07
12/02/16
17:07
Hot Stocks
Albemarle to increase prices for select brominated products »

Albemarle announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Mar

FOR

Forestar Group

$13.40

0.2 (1.52%)

17:06
12/02/16
12/02
17:06
12/02/16
17:06
Hot Stocks
Breaking Hot Stocks news story on Forestar Group »

Carlson Capital lowers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FANG

Diamondback Energy

$108.14

-1.86 (-1.69%)

17:04
12/02/16
12/02
17:04
12/02/16
17:04
Syndicate
Breaking Syndicate news story on Diamondback Energy »

Diamondback Energy files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OSIR

Osiris

$5.68

0.06 (1.07%)

17:02
12/02/16
12/02
17:02
12/02/16
17:02
Hot Stocks
Osiris: Nasdaq grants company's request for additional time »

Osiris Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STOR

STORE Capital

$24.45

0.52 (2.17%)

17:00
12/02/16
12/02
17:00
12/02/16
17:00
Hot Stocks
STORE Capital director Donovan acquires 4,350 shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CARB

Carbonite

$17.95

0.25 (1.41%)

16:48
12/02/16
12/02
16:48
12/02/16
16:48
Hot Stocks
Breaking Hot Stocks news story on Carbonite »

Crosslink lowers stake in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIB

CGI Group

$47.11

0.16 (0.34%)

16:48
12/02/16
12/02
16:48
12/02/16
16:48
Hot Stocks
CGI Group announces specific share repurchase program »

CGI Group announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

THC

Tenet

$15.05

-0.13 (-0.86%)

, UNH

UnitedHealth

$160.73

-0.21 (-0.13%)

16:45
12/02/16
12/02
16:45
12/02/16
16:45
Hot Stocks
Tenet, UnitedHealthcare renew national relationship for four years »

Tenet Healthcare (THC)…

THC

Tenet

$15.05

-0.13 (-0.86%)

UNH

UnitedHealth

$160.73

-0.21 (-0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$12.24

-0.19 (-1.53%)

16:43
12/02/16
12/02
16:43
12/02/16
16:43
Periodicals
Ford CEO willing to work with Trump to keep jobs in U.S., Bloomberg says »

Ford CEO Mark Fields said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jan

  • 10

    Jan

BAC

Bank of America

$21.23

-0.27 (-1.26%)

16:40
12/02/16
12/02
16:40
12/02/16
16:40
Options
Long-dated Bank of America calls rolled out to 2019 15 point spread »

Long-dated Bank of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 13

    Jan

DPZ

Domino's Pizza

$168.00

-0.7 (-0.41%)

16:39
12/02/16
12/02
16:39
12/02/16
16:39
Syndicate
Breaking Syndicate news story on Domino's Pizza »

Domino's Pizza files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 09

    Jan

ALKS

Alkermes

$56.25

1.36 (2.48%)

16:39
12/02/16
12/02
16:39
12/02/16
16:39
Hot Stocks
Alkermes COO and Chief Risk Officer Gordon Pugh to resign »

On November 29, Mr.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBUX

Starbucks

$57.21

-1.3 (-2.22%)

, VRX

Valeant

$15.45

0.14 (0.91%)

16:34
12/02/16
12/02
16:34
12/02/16
16:34
General news
On The Fly: Stocks end week mixed as Trump rally loses steam, oil surges »

The major averages ended…

SBUX

Starbucks

$57.21

-1.3 (-2.22%)

VRX

Valeant

$15.45

0.14 (0.91%)

GM

General Motors

$35.41

-1.02 (-2.80%)

F

Ford

$12.24

-0.19 (-1.53%)

FCAU

Fiat Chrysler

$7.63

-0.11 (-1.42%)

AAPL

Apple

$109.86

0.37 (0.34%)

AMZN

Amazon.com

$740.34

-3.31 (-0.45%)

BX

Blackstone

$25.86

-0.29 (-1.11%)

TKPYY

Takeda Pharmaceutical Co. Ltd.

$20.40

0.135 (0.67%)

TIME

Time Inc.

$16.00

-0.2 (-1.23%)

LNEGY

Linde

$16.77

0.09 (0.54%)

PX

Praxair

$119.58

-0.15 (-0.13%)

PH

Parker-Hannifin

$141.90

-1.57 (-1.09%)

CLC

Clarcor

$82.46

-0.12 (-0.15%)

TIF

Tiffany

$81.30

-1.21 (-1.47%)

THO

Thor Industries

$101.48

-1.5 (-1.46%)

SPLK

Splunk

$53.68

0.35 (0.66%)

ASNA

Ascena Retail

$7.01

1.18 (20.24%)

FIVE

Five Below

$43.82

3.94 (9.88%)

MNK

Mallinckrodt

$53.61

0.51 (0.96%)

AEO

American Eagle

$16.17

-0.57 (-3.41%)

ADSK

Autodesk

$70.57

1.35 (1.95%)

DG

Dollar General

$74.56

1.08 (1.47%)

EXPR

Express

$10.79

0.15 (1.41%)

GES

Guess

$12.91

-0.85 (-6.18%)

WDAY

Workday

$71.40

-10.2 (-12.50%)

ULTA

Ulta Beauty

$253.39

-4.02 (-1.56%)

AMBA

Ambarella

$54.47

-6.92 (-11.27%)

SWHC

Smith & Wesson

$21.10

-2.88 (-12.01%)

UNH

UnitedHealth

$160.73

-0.21 (-0.13%)

CAT

Caterpillar

$95.14

-1.1 (-1.14%)

JPM

JPMorgan

$81.60

-0.19 (-0.23%)

BLK

BlackRock

$371.36

-5.84 (-1.55%)

DIS

Disney

$98.50

-0.44 (-0.44%)

WMT

Wal-Mart

$70.88

0.21 (0.30%)

IBM

IBM

$160.02

0.2 (0.13%)

CTSH

Cognizant

$54.02

-0.06 (-0.11%)

T

AT&T

$38.61

-0.27 (-0.69%)

TWX

Time Warner

$93.80

-0.34 (-0.36%)

GPRO

GoPro

$9.70

-0.12 (-1.22%)

NSANY

Nissan

$18.68

-0.05 (-0.27%)

TM

Toyota

$116.83

-0.94 (-0.80%)

VLKAY

Volkswagen

$27.18

-0.05 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 05

    Dec

  • 05

    Dec

  • 06

    Dec

  • 06

    Dec

  • 06

    Dec

  • 07

    Dec

  • 07

    Dec

  • 07

    Dec

  • 07

    Dec

  • 07

    Dec

  • 08

    Dec

  • 08

    Dec

  • 08

    Dec

  • 12

    Dec

  • 13

    Dec

  • 13

    Dec

  • 13

    Dec

  • 14

    Dec

  • 14

    Dec

  • 19

    Dec

  • 20

    Dec

  • 05

    Jan

  • 09

    Jan

  • 09

    Jan

  • 10

    Jan

  • 13

    Jan

  • 16

    Feb

  • 28

    Feb

  • 13

    Mar

  • 14

    Jul

  • 12

    Oct

CASI

CASI Pharmaceuticals

$1.35

0.1009 (8.07%)

16:33
12/02/16
12/02
16:33
12/02/16
16:33
Syndicate
Breaking Syndicate news story on CASI Pharmaceuticals »

CASI Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCLP

Hi-Crush Partners

$18.40

0.6 (3.37%)

16:31
12/02/16
12/02
16:31
12/02/16
16:31
Syndicate
Breaking Syndicate news story on Hi-Crush Partners »

Hi-Crush Partners files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCLP

Hi-Crush Partners

$18.40

0.6 (3.37%)

16:31
12/02/16
12/02
16:31
12/02/16
16:31
Syndicate
Breaking Syndicate news story on Hi-Crush Partners »

Hi-Crush Partners files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
12/02/16
12/02
16:30
12/02/16
16:30
Options
Preliminary option volume of 15.6M today »

Preliminary option volume…

SBUX

Starbucks

$57.21

-1.3 (-2.22%)

, WDAY

Workday

$71.40

-10.2 (-12.50%)

16:28
12/02/16
12/02
16:28
12/02/16
16:28
General news
On The Fly: Top stock stories for Friday »

Stocks began the day with…

SBUX

Starbucks

$57.21

-1.3 (-2.22%)

WDAY

Workday

$71.40

-10.2 (-12.50%)

P

Pandora

$13.33

1.85 (16.12%)

SIRI

Sirius XM

$4.30

-0.255 (-5.60%)

ULTA

Ulta Beauty

$253.39

-4.02 (-1.56%)

BX

Blackstone

$25.86

-0.29 (-1.11%)

GM

General Motors

$35.41

-1.02 (-2.80%)

JPM

JPMorgan

$81.60

-0.19 (-0.23%)

BLK

BlackRock

$371.36

-5.84 (-1.55%)

DIS

Disney

$98.50

-0.44 (-0.44%)

WMT

Wal-Mart

$70.88

0.21 (0.30%)

IBM

IBM

$160.02

0.2 (0.13%)

INFO

IHS Markit

$34.88

-0.23 (-0.66%)

ASNA

Ascena Retail

$7.01

1.18 (20.24%)

FIVE

Five Below

$43.82

3.94 (9.88%)

AMBA

Ambarella

$54.47

-6.92 (-11.27%)

SWHC

Smith & Wesson

$21.10

-2.88 (-12.01%)

ATI

Allegheny Technologies

$16.93

-0.83 (-4.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

  • 07

    Dec

  • 07

    Dec

  • 07

    Dec

  • 08

    Dec

  • 08

    Dec

  • 13

    Dec

  • 13

    Dec

  • 14

    Dec

  • 09

    Jan

  • 09

    Jan

  • 10

    Jan

  • 13

    Jan

  • 28

    Feb

  • 14

    Jul

  • 12

    Oct

FLDM

Fluidigm

$6.68

0.2 (3.09%)

16:25
12/02/16
12/02
16:25
12/02/16
16:25
Hot Stocks
Fluidigm CEO acquires 55,000 shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSON

Hudson Global

$1.47

0.01 (0.68%)

16:25
12/02/16
12/02
16:25
12/02/16
16:25
Hot Stocks
Sagard exits stake in Hudson Global »

This was reported in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLA

Delta Apparel

$21.39

0.24 (1.13%)

16:22
12/02/16
12/02
16:22
12/02/16
16:22
Hot Stocks
Delta Apparel chief accounting officer DuVall resigns »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

$14.03

-0.04 (-0.28%)

16:20
12/02/16
12/02
16:20
12/02/16
16:20
Options
Closing CBOE SPX and VIX Index summary for December 2nd »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EW

Edwards Lifesciences

$83.35

1.88 (2.31%)

16:19
12/02/16
12/02
16:19
12/02/16
16:19
Hot Stocks
Edward Lifesciences' Szyman acquires 12,870 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

$NYE

NYSE Market Internals

16:16
12/02/16
12/02
16:16
12/02/16
16:16
Technical Analysis
NYSE market internals summary »

Breadth is bullish across…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.